相关实验视频

Updated: Jan 18, 2026

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

两种肥胖综合征之间的代谢物差异的初步研究基于Q 精确液体染色学-并联质谱学代谢学

Ye Jing¹, Xiaoxuan Xu², Yanhong Wang³

¹Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.

|September 10, 2025

概括

这项研究确定了Shi和Xu肥胖症的独特血清代谢物概况,揭示了这些传统中医药分类中的新生物标志物,如L-tyrosine和glycerophosphocholine.

科学领域:

代谢学代谢学代谢学
传统中国医药传统中国医药
肥胖问题研究研究

背景情况:

在中国传统医学中,肥胖症根据病原和临床表现被分为"shi"或"xu".
了解这些肥胖类型之间的代谢差异对于有针对性的治疗至关重要.

研究的目的:

为了研究和比较患者的血清代谢物水平与肥胖和肥胖.
为了确定区分这些肥胖亚型的潜在代谢生物标志物.

主要方法:

来自健康成年人,肥胖患者和肥胖患者的血清样本使用Q精确液体染色学-双重质谱分析.
使用人类代谢数据库和基因和基因组的京都百科全书来确定代谢途径.

主要成果:

确定了15种潜在的血清生物标志物,其中14种显示上调.
fenilalanine,L-tyrosine,glycerophosphocholine和LysoPC ((O-18:0/0:0) 与这两种肥胖类型都有显著的相关性.
鉴定出L-氨酸和甘氨酸胆是新型的潜在生物标志物,用于Shi和Xu肥胖.

结论:

血清代谢物的显著差异存在于shi和xu肥胖之间.
鉴定的生物标志物为开发针对不同类型肥胖的有针对性的治疗策略提供了潜力.

更多相关视频

Untargeted Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High Resolution Mass Spectrometry UPLC-HRMS

Untargeted Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High Resolution Mass Spectrometry UPLC-HRMS

Published on: May 20, 2013

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Large Scale Non-targeted Metabolomic Profiling of Serum by Ultra Performance Liquid Chromatography-Mass Spectrometry UPLC-MS

Published on: March 14, 2013

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...